Loading...

We've got a brand new version of Simply Wall St! Try it out

Genovate Biotechnology

GTSM:4130
Snowflake Description

Flawless balance sheet with questionable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4130
GTSM
NT$3B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
4130 Share Price and Events
7 Day Returns
1%
GTSM:4130
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
-1.5%
GTSM:4130
16%
TW Pharmaceuticals
17.7%
TW Market
4130 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genovate Biotechnology (4130) 1% 7.1% -2.3% -1.5% -29.7% -54.8%
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 4130 underperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 4130 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4130
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Genovate Biotechnology's competitors could be found in our database.

4130 Value

 Is Genovate Biotechnology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Genovate Biotechnology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Genovate Biotechnology.

GTSM:4130 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in TWD NT$ .285700
Payout Ratio Company Filings (2019-09-30) 8308.8%
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4130
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (0.05%))
0.794
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for GTSM:4130 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Genovate Biotechnology is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

GTSM:4130 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= NT$0.29 / (7.5% - 2.73%)
NT$4.17
GTSM:4130 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$4.17
Current discount Discount to share price of NT$25.70
= -1 x (NT$25.70 - NT$4.17) / NT$4.17
-517%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Genovate Biotechnology is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genovate Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genovate Biotechnology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4130 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$0.37
GTSM:4130 Share Price ** GTSM (2019-11-18) in TWD NT$25.7
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genovate Biotechnology.

GTSM:4130 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4130 Share Price ÷ EPS (both in TWD)

= 25.7 ÷ 0.37

69.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genovate Biotechnology is overvalued based on earnings compared to the TW Pharmaceuticals industry average.
  • Genovate Biotechnology is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Genovate Biotechnology's expected growth come at a high price?
Raw Data
GTSM:4130 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 69.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
19.4%per year
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genovate Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genovate Biotechnology's assets?
Raw Data
GTSM:4130 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$15.35
GTSM:4130 Share Price * GTSM (2019-11-18) in TWD NT$25.7
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:4130 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4130 Share Price ÷ Book Value per Share (both in TWD)

= 25.7 ÷ 15.35

1.67x

* Primary Listing of Genovate Biotechnology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genovate Biotechnology is good value based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Genovate Biotechnology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Genovate Biotechnology has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4130 Future Performance

 How is Genovate Biotechnology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Genovate Biotechnology, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genovate Biotechnology expected to grow at an attractive rate?
  • Genovate Biotechnology's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Genovate Biotechnology's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • Unable to compare Genovate Biotechnology's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4130 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:4130 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 19.4%
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4130 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4130 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
GTSM:4130 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 470 26 39
2019-06-30 467 39 63
2019-03-31 464 37 58
2018-12-31 456 63 58
2018-09-30 443 91 96
2018-06-30 439 87 98
2018-03-31 434 39 158
2017-12-31 408 31 149
2017-09-30 412 16 112
2017-06-30 420 50 90
2017-03-31 414 93 29
2016-12-31 411 71 39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genovate Biotechnology's earnings are expected to grow by 19.4% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Genovate Biotechnology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4130 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Genovate Biotechnology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4130 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
GTSM:4130 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 0.37
2019-06-30 0.60
2019-03-31 0.55
2018-12-31 0.55
2018-09-30 0.92
2018-06-30 0.93
2018-03-31 1.50
2017-12-31 1.42
2017-09-30 1.06
2017-06-30 0.85
2017-03-31 0.27
2016-12-31 0.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genovate Biotechnology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Genovate Biotechnology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genovate Biotechnology has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4130 Past Performance

  How has Genovate Biotechnology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genovate Biotechnology's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genovate Biotechnology's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Genovate Biotechnology's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Genovate Biotechnology's 1-year earnings growth is negative, it can't be compared to the TW Pharmaceuticals industry average.
Earnings and Revenue History
Genovate Biotechnology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genovate Biotechnology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4130 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 469.69 38.68 96.30 68.82
2019-06-30 467.11 63.33 99.73 64.46
2019-03-31 463.96 58.25 101.66 62.00
2018-12-31 455.80 57.85 102.32 61.07
2018-09-30 442.99 96.45 108.62 60.36
2018-06-30 439.31 97.61 111.65 56.91
2018-03-31 433.64 157.91 112.14 53.31
2017-12-31 408.27 148.97 111.31 51.45
2017-09-30 411.58 111.90 106.47 37.28
2017-06-30 420.23 90.13 99.63 38.80
2017-03-31 413.63 28.84 95.57 44.39
2016-12-31 411.20 39.21 95.13 54.83
2016-09-30 438.61 40.74 100.58 63.40
2016-06-30 442.63 48.98 101.09 65.72
2016-03-31 451.74 50.84 103.34 66.74
2015-12-31 477.60 46.49 106.30 58.07
2015-09-30 454.37 44.12 109.35 51.29
2015-06-30 466.70 52.04 111.53 49.68
2015-03-31 478.71 69.60 113.13 46.02
2014-12-31 475.45 72.53 112.00 43.62
2014-09-30 463.66 73.27 105.02 39.16
2014-06-30 442.57 63.21 104.35 33.70
2014-03-31 418.64 55.93 102.07 32.53
2013-12-31 397.04 45.66 100.37 31.81
2013-09-30 381.54 43.95 99.95 30.81
2013-06-30 363.42 73.35 98.31 35.79
2013-03-31 353.66 63.05 96.16 35.73
2012-12-31 348.29 60.67 93.14 40.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Genovate Biotechnology has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Genovate Biotechnology used its assets less efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Genovate Biotechnology has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Genovate Biotechnology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genovate Biotechnology has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4130 Health

 How is Genovate Biotechnology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genovate Biotechnology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genovate Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genovate Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genovate Biotechnology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Genovate Biotechnology has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genovate Biotechnology Company Filings, last reported 1 month ago.

GTSM:4130 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,496.71 0.00 459.09
2019-06-30 1,519.05 0.00 506.73
2019-03-31 1,555.44 0.00 456.60
2018-12-31 1,563.49 0.00 472.00
2018-09-30 1,662.17 0.00 456.44
2018-06-30 1,835.09 0.00 542.28
2018-03-31 1,786.81 0.00 583.98
2017-12-31 1,599.67 250.00 807.78
2017-09-30 1,797.10 248.40 704.94
2017-06-30 1,921.22 246.80 699.56
2017-03-31 1,912.74 245.22 675.69
2016-12-31 2,249.28 243.65 718.96
2016-09-30 2,477.42 242.09 695.19
2016-06-30 2,577.01 240.54 777.09
2016-03-31 2,636.75 238.99 779.20
2015-12-31 2,124.31 237.46 764.03
2015-09-30 1,336.61 235.94 753.96
2015-06-30 1,339.18 234.42 846.80
2015-03-31 1,413.64 232.92 849.03
2014-12-31 1,199.07 231.43 660.10
2014-09-30 1,067.79 0.00 394.83
2014-06-30 1,043.16 0.00 492.28
2014-03-31 1,048.60 0.00 527.48
2013-12-31 1,024.11 0.00 526.92
2013-09-30 1,022.23 0.00 506.62
2013-06-30 1,008.52 0.00 565.68
2013-03-31 1,026.17 0.00 571.47
2012-12-31 1,013.29 0.00 578.27
  • Genovate Biotechnology has no debt.
  • Genovate Biotechnology has no debt compared to 5 years ago when it was 0.2%.
  • Genovate Biotechnology has no debt, it does not need to be covered by operating cash flow.
  • Genovate Biotechnology has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Genovate Biotechnology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genovate Biotechnology has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4130 Dividends

 What is Genovate Biotechnology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.11%
Current annual income from Genovate Biotechnology dividends.
If you bought NT$2,000 of Genovate Biotechnology shares you are expected to receive NT$22 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Genovate Biotechnology's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.57%).
  • Genovate Biotechnology's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4130 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4130 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
GTSM:4130 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-28 0.286 1.080
2019-03-27 0.286 1.034
2018-03-23 0.762 2.580
2017-03-31 0.333 0.983
2016-03-17 0.476 1.158
2015-03-19 0.476 1.022
2014-05-14 0.286 0.509
2014-03-27 0.286 0.822
2013-03-28 0.286 0.747

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genovate Biotechnology is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are stable.
  • Genovate Biotechnology is not paying a notable dividend for Taiwan, Province of China, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Genovate Biotechnology's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Genovate Biotechnology's dividends as it is not paying a notable one for Taiwan, Province of China.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genovate Biotechnology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genovate Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genovate Biotechnology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4130 Management

 What is the CEO of Genovate Biotechnology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Genovate Biotechnology has no CEO, or we have no data on them.
Management Team

Chen Zheng

TITLE
Chairman and General Manager

Ming Gui Peng

TITLE
Deputy General Manager of Operations
Board of Directors

Chen Zheng

TITLE
Chairman and General Manager

Hui Po Wang

TITLE
Director
TENURE
13.2 yrs

Zhong Xin Gong

TITLE
Director
TENURE
13.4 yrs

Rong Jiang Liang

TITLE
Director

Ning Sun Yang

TITLE
Director

Chin-Miao Lin

TITLE
Director

Zhen Zhang

TITLE
Director

Shi Li Huang

TITLE
Director

Yu Sheng Zhao

TITLE
Director

Qi Neng Zhang

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Genovate Biotechnology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genovate Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4130 News

Simply Wall St News

4130 Company Info

Description

Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan. It offers central nervous system drugs, cardiovascular drugs, musculoskeletal system drugs, immunological preparation, anti-infective agents, anticancer drugs, anti-viral drugs, respiratory medicines, genitourinary system drugs, and gastrointestinal drugs. The company was founded in 1995 and is based in Hsinchu County, Taiwan.

Details
Name: Genovate Biotechnology Co., Ltd.
4130
Exchange: GTSM
Founded: 1995
NT$2,703,303,330
105,186,900
Website: http://www.genovate-bio.com
Address: Genovate Biotechnology Co., Ltd.
No.1, Industrial First Road,
Hsinchu Industrial Zone,
Hsinchu,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4130 Common Stock Taipei Exchange TW TWD 20. Jul 2007
Number of employees
Current staff
Staff numbers
176
Genovate Biotechnology employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 15:04
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2018/03/20
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.